Horizon Discovery
Helen Pemberton is an accomplished professional in the field of cell-based screening with extensive experience in project management and high-throughput screening. Currently serving as Manager of Cell Based Screening at Revvity since May 2023, Pemberton has previously held a similar position at Horizon Discovery since July 2017, where key responsibilities included coordinating the OncoSignature and custom arrayed compound screening projects. Prior to that, at The Institute of Cancer Research, Pemberton advanced from Higher Scientific Officer to Senior Scientific Officer, focusing on high-throughput genetic and drug screening for the Gene Function Team. Early career roles included a Postdoctoral Research Fellow at Cancer Research UK and a PhD at the University of Birmingham. Pemberton holds a Bachelor's Degree in Biochemistry and Molecular Biology from Durham University.
This person is not in any offices
Horizon Discovery
2 followers
Horizon builds human disease models and reagents derived from genetically-engineered cells that its customers use, or that are deployed on their behalf to: gain knowledge of the genetic drivers of disease; develop novel drugs or cell therapies targeted.